(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
30 September 2021 (30.09.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/195475 A1

(51) International Patent Classification:
A61K 31/444 (2006.01) *A01N 43/54* (2006.01)
A61K 31/506 (2006.01)

(21) International Application Number:
PCT/US2021/024316

(22) International Filing Date:
26 March 2021 (26.03.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/000,746	27 March 2020 (27.03.2020)	US
63/015,241	24 April 2020 (24.04.2020)	US
63/018,954	01 May 2020 (01.05.2020)	US
63/022,298	08 May 2020 (08.05.2020)	US
63/022,301	08 May 2020 (08.05.2020)	US
63/024,160	13 May 2020 (13.05.2020)	US
63/053,903	20 July 2020 (20.07.2020)	US
63/076,689	10 September 2020 (10.09.2020)	US
63/126,173	16 December 2020 (16.12.2020)	US
63/128,523	21 December 2020 (21.12.2020)	US
63/136,080	11 January 2021 (11.01.2021)	US
63/136,967	13 January 2021 (13.01.2021)	US
63/138,672	18 January 2021 (18.01.2021)	US
63/140,116	21 January 2021 (21.01.2021)	US
63/149,230	13 February 2021 (13.02.2021)	US


(71) Applicant: **ACLARIS THERAPEUTICS, INC.** [US/US]; 640 Lee Road, Suite 200, Wayne, Pennsylvania 19087 (US).

(72) Inventors: **DECRESCENZO, Gary A.**; 6135 Westwood Court, Parkville, Missouri 54152 (US). **SPRINGER, John Robert**; 203 Willow Park Drive, Wentzville, Missouri 63385 (US). **HOCKERMAN, Susan Landis**; 636 Pearl Ave, Kirkwood, Missouri 63122 (US).

(74) Agent: **FRATTINI, Gregory D.** et al.; Troutman Pepper Hamilton Sanders LLP, 501 Grant Street, Suite 300, Union Trust Building, Pittsburgh, 15219-4429 (US).

(54) Title: PROCESS, COMPOSITIONS, AND CRYSTALLINE FORMS OF SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS

FIGURE 1



(57) Abstract: The present disclosure provides a crystalline form of the methyl/fluoro-pyridinyl-methoxy substituted pyridinone-pyridinyl compound of the structure: XRPD, TGA, and DSC data on the crystalline form, as well as methods preparing the crystalline form, including a multi-kilo scale preparation. Also provided are pharmaceutical compositions and methods of treating p38 mediated diseases, such as lymphoma and auto-inflammatory disease, including rheumatoid arthritis. and methods of maximizing the yield thereof comprising administering of the compound. Also provided is a method of maximizing the yield of said compound via a recycling procedure.

WO 2021/195475 A1

[Continued on next page]

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*